03323nas a2200433   4500000000100000008004100001260002500042653001900067653002600086653002200112653001700134100001600151700001500167700001300182700001200195700001300207700001900220700001500239700001600254700001800270700001500288700002000303700001200323700001300335700001400348700001500362700001500377700001400392700001500406700001400421700001400435700001600449245007600465856007900541300000800620490000700628520224000635022001402875       2024                            d  bUbiquity Press, Ltd.10aChagas disease10aChagas Cardiomyopathy10aBurden of Disease10aEpidemiology1 aRibeiro ALP1 aMachado Í1 aCousin E1 aPerel P1 aDemacq C1 aGeissbühler Y1 ade Souza A1 aLiprandi AS1 aNascimento BR1 aFrança EF1 aMartins-Melo FR1 aRoth GA1 aMolina I1 aNoronha K1 aIshitani L1 aCarneiro M1 aQuijano M1 aAndrade MV1 aNaghavi M1 aMosser JF1 aPiñeiro DJ00aThe Burden of Chagas Disease in the Contemporary World: The RAISE Study  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785959/pdf/gh-19-1-1280.pdf  a1-60 v193 a<p>Chagas disease (ChD), a Neglected Tropical Disease, has witnessed a transformative epidemiological landscape characterized by a trend of reduction in prevalence, shifting modes of transmission, urbanization, and globalization. Historically a vector-borne disease in rural areas of Latin America, effective control measures have reduced the incidence in many countries, leading to a demographic shift where most affected individuals are now adults. However, challenges persist in regions like the Gran Chaco, and emerging oral transmission in the Amazon basin adds complexity. Urbanization and migration from rural to urban areas and to non-endemic countries, especially in Europe and the US, have redefined the disease’s reach. These changing patterns contribute to uncertainties in estimating ChD prevalence, exacerbated by the lack of recent data, scarcity of surveys, and reliance on outdated models. Besides, ChD’s lifelong natural history, marked by acute and chronic phases, introduces complexities in diagnosis, particularly in non-endemic regions where healthcare provider awareness is low. The temporal dissociation of infection and clinical manifestations, coupled with underreporting, has rendered ChD invisible in health statistics. Deaths attributed to ChD cardiomyopathy often go unrecognized, camouflaged under alternative causes. Understanding these challenges, the RAISE project aims to reassess the burden of ChD and ChD cardiomyopathy. The project is a collaborative effort of the World Heart Federation, Novartis Global Health, the University of Washington’s Institute for Health Metrics and Evaluation, and a team of specialists coordinated by Brazil’s Federal University of Minas Gerais. Employing a multidimensional strategy, the project seeks to refine estimates of ChD-related deaths, conduct systematic reviews on seroprevalence and prevalence of clinical forms, enhance existing modeling frameworks, and calculate the global economic burden, considering healthcare expenditures and service access. The RAISE project aspires to bridge knowledge gaps, raise awareness, and inform evidence-based health policies and research initiatives, positioning ChD prominently on the global health agenda.</p>
  a2211-8179